SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precise Autophagy Inhibition

Executive Summary: SAR405 is a nanomolar-potency, ATP-competitive inhibitor of Vps34, a class III phosphoinositide 3-kinase (PI3K) essential for autophagy regulation and vesicle trafficking (APExBIO). The compound demonstrates a dissociation constant (Kd) of 1.5 nM and an IC₅₀ of 1 nM against human recombinant Vps34, with no inhibition observed for class I or II PI3Ks or mTOR at concentrations up to 10 μM (Park et al., 2023). SAR405 impairs autophagosome formation and lysosome function, leading to vesicle trafficking defects and cathepsin D maturation failure. The inhibitor's selectivity and solubility properties make it an ideal tool for studying Vps34 kinase signaling, cancer biology, and neurodegenerative disease models (Vatalis, 2023).

Biological Rationale

Autophagy is a conserved catabolic process crucial for cellular homeostasis, especially during nutrient or energy stress (Park et al., 2023). Vps34, the only class III PI3K, generates phosphatidylinositol 3-phosphate (PI3P), essential for autophagosome membrane nucleation and vesicular trafficking. Class I and II PI3Ks and mTOR complex 1 (mTORC1) regulate other aspects of cell growth and metabolism but are not directly involved in autophagosome formation. Selective inhibition of Vps34 allows researchers to dissect the autophagy pathway without off-target effects on other PI3K isoforms or mTOR (Vatalis, 2023). Dysregulation of autophagy and vesicle trafficking is implicated in cancer progression, neurodegeneration, and lysosomal storage disorders.

Mechanism of Action of SAR405

SAR405 is a potent, ATP-competitive inhibitor that binds within the ATP-binding cleft of Vps34, blocking its kinase activity (APExBIO). This selective inhibition disrupts the formation of PI3P on endomembranes, impairing the recruitment of downstream autophagy machinery components such as WIPI2 and ATG proteins. As a result, autophagosome nucleation is blocked, and the autophagic flux is arrested at an early stage. In cell models (GFP-LC3 HeLa, H1299), SAR405 treatment leads to the accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation, indicating impaired vesicle trafficking and lysosome function (Laminin, 2023). SAR405 does not inhibit class I/II PI3Ks or mTOR, ensuring pathway specificity. The compound synergizes with mTOR inhibitors such as everolimus, providing a dual blockade of autophagy induction and progression.

Evidence & Benchmarks

• SAR405 exhibits a Kd of 1.5 nM and an IC₅₀ of 1 nM against recombinant human Vps34, demonstrating nanomolar potency and exquisite selectivity (APExBIO).
• No inhibition of class I/II PI3Ks or mTOR is observed at concentrations up to 10 μM, establishing pathway specificity (Park et al., 2023).
• Treatment with SAR405 leads to the blockade of autophagosome formation, as shown by reduced GFP-LC3 puncta in HeLa and H1299 cells (Park et al., 2023).
• SAR405 causes defective cathepsin D maturation and accumulation of late endosome-lysosomes, indicating impaired lysosomal function (Vatalis, 2023).
• The compound is soluble in DMSO (>10 mM), insoluble in water, and soluble in ethanol with ultrasonic assistance (APExBIO).
• Synergistic inhibition of autophagy is observed when SAR405 is combined with mTOR inhibitors in multiple cell models (Vatalis, 2023).

Applications, Limits & Misconceptions

SAR405 is widely used for mechanistic studies of autophagy inhibition, vesicle trafficking modulation, and the Vps34 signaling pathway in cancer research and neurodegenerative disease models (GDC0068, 2023). Compared to older PI3K inhibitors, SAR405 allows for precise dissection of class III PI3K-dependent processes without confounding effects on other PI3K isoforms or mTOR. This article extends the discussion in 'SAR405 and the Vps34 Kinase Pathway' by providing updated benchmarks and direct comparisons of selectivity profiles.

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I or II PI3Ks or mTOR at concentrations up to 10 μM; it is not suitable for broad PI3K pathway inhibition (Park et al., 2023).
• It cannot distinguish between Vps34-dependent autophagy and other forms of non-canonical autophagy (e.g., those not requiring PI3P).
• SAR405 is ineffective in experimental systems lacking functional Vps34 or in models with compensatory autophagy pathways.
• Long-term storage of SAR405 solutions at room temperature leads to compound degradation, reducing efficacy (APExBIO).
• The compound is insoluble in aqueous media; improper dissolution protocols may result in precipitation and variable results.

Workflow Integration & Parameters

SAR405 (SKU A8883) is supplied by APExBIO as a lyophilized powder. Stock solutions should be prepared in DMSO at concentrations >10 mM and stored at –20°C for several months. For cell-based assays, typical working concentrations range from 10 nM to 1 μM, with DMSO final concentration kept below 0.1% to minimize solvent effects. The inhibitor is compatible with standard autophagy and vesicle trafficking assays, including GFP-LC3 puncta formation, cathepsin D maturation, and endosome-lysosome colocalization. Ethanol can be used for dissolution with ultrasonic assistance if DMSO is not suitable. For advanced workflow integration and troubleshooting, see this protocol guide, which details optimization in various disease models and clarifies experimental boundaries versus previous approaches.

Conclusion & Outlook

SAR405 provides unmatched selectivity and potency for Vps34 inhibition, enabling precise investigation of autophagy, vesicle trafficking, and lysosome function in cancer and neurodegeneration research. Its robust biochemical profile and compatibility with mTOR inhibitors make SAR405 a foundational tool in both mechanistic and translational studies. As new evidence emerges on autophagy signaling complexity, SAR405’s specificity will remain critical for dissecting divergent pathways and for benchmarking future pharmacological modulators (Park et al., 2023). For further reading, see this scenario-driven guide which contrasts SAR405’s use with newly emerging Vps34 inhibitors, and clarifies its value for reproducible, high-sensitivity workflows.